Erin Hedin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erin Hedin has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Adeera Levin
Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, Canada
2 shared publicationsFeng Ye
Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
2 shared publicationsHarley Crowshoe
Alberta Health Services/Acute Care Alberta, Calgary, Canada
2 shared publications- Ikechi G. Okpechi
Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
2 shared publications Marcello Tonelli
Department of Medicine, University of Calgary, Calgary, AB, Canada
2 shared publications- Robin Erickson
Starship Children's Hospital, Auckland, New Zealand
2 shared publications
Latest Publications
- Open Access
- 30 May 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Integrated, Community-Led, Culturally Safe Implementation of a Chronic Kidney Disease Detection Program for Indigenous Communities of Canada: The Kidney Check Program Report
Purpose of program: Indigenous peoples in Canada experience a disproportionate burden of chronic kidney disease (CKD) yet face systemic, geographic, and cultural barriers to early detection and care. The Kidney Check program was established as a national initiative to address this gap by providing community-led, culturally safe, and integrated chronic disease screening. Sources of information: Kidney Check builds on the success of the First Nations Community-Based Screening to Improve Kidney Health and Prevent Dialysis (FINISHED) study in Manitoba and was expanded through the Can-SOLVE CKD Network. This report summarizes updated data from April 2023 to March 2024, capturing the implementation of Kidney Check across five provinces: Alberta (AB), British Columbia (BC), Manitoba (MB), Ontario (ON), and Saskatchewan (SK). Data sources include provincial program records, training logs, process measures, referral data, patient and provider testimonials, and qualitative evaluations from community members, providers, and patient partners. Methods: Kidney Check applies a standardized, mobile, point-of-care-testing (POCT)-based screening protocol for CKD, diabetes, and hypertension, adapted locally in collaboration with Indigenous communities. Implementation followed principles of Indigenous governance, data sovereignty (Ownership, Control, Access, Possession [OCAP]), and Two-Eyed Seeing, where both Western and Indigenous medicines and ways are acknowledged, respected, and practiced, with provincial adaptations tailored to local contexts. Information was synthesized across jurisdictions to identify process measures, barriers and facilitators to implementation, and early outcomes. Key findings: Since program inception, thousands of Indigenous participants have been screened across more than 50 communities. AB and BC demonstrated scale-up through train-the-trainer and community-embedded models, training over 30 providers and screening >700 participants in BC alone. Manitoba built on the FINISHED study to deliver screening in 10 communities, with nearly 700 participants screened. Ontario resumed screening in 2024, with >250 participants screened across five regional renal programs. Saskatchewan launched Kidney Check in 2023, screening 230 participants, with early identification of intermediate- and high-risk individuals. Across sites, facilitators included strong community partnerships, local hiring, and integration with existing health services. Barriers included logistical challenges (equipment, travel, quality assurance and quality control [QA/QC]), staffing constraints, and sustainability concerns. Limitations: Variation in infrastructure, referral pathways, and data systems across provinces limits cross-jurisdictional comparability. Long-term outcome data (eg, CKD progression, cardiovascular events, mortality) are not yet available. Implications: The Kidney Check program demonstrates that culturally safe, community-led, POCT-based screening for CKD and related chronic diseases is feasible, acceptable, and scalable across diverse Indigenous communities in Canada. Lessons learned highlight the central importance of Indigenous leadership, cultural safety, and flexible delivery models to advance health equity.
- 30 May 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Open AccessIntegrated, Community-Led, Culturally Safe Implementation of a Chronic Kidney Disease Detection Program for Indigenous Communities of Canada: The Kidney Check Program Report
Purpose of program: Indigenous peoples in Canada experience a disproportionate burden of chronic kidney disease (CKD) yet face systemic, geographic, and cultural barriers to early detection and care. The Kidney Check program was established as a national initiative to address this gap by providing community-led, culturally safe, and integrated chronic disease screening. Sources of information: Kidney Check builds on the success of the First Nations Community-Based Screening to Improve Kidney Health and Prevent Dialysis (FINISHED) study in Manitoba and was expanded through the Can-SOLVE CKD Network. This report summarizes updated data from April 2023 to March 2024, capturing the implementation of Kidney Check across five provinces: Alberta (AB), British Columbia (BC), Manitoba (MB), Ontario (ON), and Saskatchewan (SK). Data sources include provincial program records, training logs, process measures, referral data, patient and provider testimonials, and qualitative evaluations from community members, providers, and patient partners. Methods: Kidney Check applies a standardized, mobile, point-of-care-testing (POCT)-based screening protocol for CKD, diabetes, and hypertension, adapted locally in collaboration with Indigenous communities. Implementation followed principles of Indigenous governance, data sovereignty (Ownership, Control, Access, Possession [OCAP]), and Two-Eyed Seeing, where both Western and Indigenous medicines and ways are acknowledged, respected, and practiced, with provincial adaptations tailored to local contexts. Information was synthesized across jurisdictions to identify process measures, barriers and facilitators to implementation, and early outcomes. Key findings: Since program inception, thousands of Indigenous participants have been screened across more than 50 communities. AB and BC demonstrated scale-up through train-the-trainer and community-embedded models, training over 30 providers and screening >700 participants in BC alone. Manitoba built on the FINISHED study to deliver screening in 10 communities, with nearly 700 participants screened. Ontario resumed screening in 2024, with >250 participants screened across five regional renal programs. Saskatchewan launched Kidney Check in 2023, screening 230 participants, with early identification of intermediate- and high-risk individuals. Across sites, facilitators included strong community partnerships, local hiring, and integration with existing health services. Barriers included logistical challenges (equipment, travel, quality assurance and quality control [QA/QC]), staffing constraints, and sustainability concerns. Limitations: Variation in infrastructure, referral pathways, and data systems across provinces limits cross-jurisdictional comparability. Long-term outcome data (eg, CKD progression, cardiovascular events, mortality) are not yet available. Implications: The Kidney Check program demonstrates that culturally safe, community-led, POCT-based screening for CKD and related chronic diseases is feasible, acceptable, and scalable across diverse Indigenous communities in Canada. Lessons learned highlight the central importance of Indigenous leadership, cultural safety, and flexible delivery models to advance health equity.
- Open Access
- 27 July 2025
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 12
Impacts of the COVID-19 Pandemic on Chronic Kidney Disease Care: Perspectives of Health Care Providers
Background: The COVID-19 pandemic significantly disrupted health care delivery; however, limited research attention has addressed the impacts of the pandemic specifically on renal-based health care. Objective: The aim of the study was to understand the health and psychosocial impacts of the COVID-19 pandemic on care delivery as well as on health care providers (HCPs). Design: A qualitative Interpretive Description approach was used. Setting: Participants were recruited from kidney care units in Alberta and Ontario, Canada. Participants: 46 interdisciplinary HCPs providing kidney care during the pandemic participated in the study. Participants comprised pediatric (n=9) and adult (n=37) HCPs. Methods: Qualitative focus groups were facilitated. They were conducted using Zoom (Version 6.3.11). Results: Research results indicated substantial strain on patients and HCPs during the COVID-19 pandemic, including mental health difficulties. For HCPs, moral distress was experienced from witnessing negative impacts of the pandemic and care shifts on patients. HCPs were further deleteriously affected by staffing shortages, facility limitations due to care interruptions and resource gaps in health and community systems. Conversely, participants identified concurrent benefits from pandemic-related shifts such as the rapid transition to virtual care. While virtual care imposed challenges for physical assessment of patients, patient convenience and increased access to HCPs were noted. With training, support and experience, HCPs and patients reported an appreciation for communication offered by virtual care where appropriate. Supportive unit leaders and peer support from HCP colleagues were viewed to make this difficult experience of the pandemic more manageable. HCPs drew strength in being able to support their patients despite the difficulties of the pandemic. Limitations: Firsthand experiences of patients and families were not offered in this article, although their perspectives were elicited in another arm of this study. A more specific focus on pediatric versus adult systems of care, and the impacts of the pandemic on various disciplines, would add depth to understanding the unique impacts of the pandemic on various areas of care and across disciplines. Conclusions: Study results call for the advancement of clinical care and heightened consideration of HCP needs in a pandemic. Included recommendations are ensuring sufficient resources, prudent use of communication technology, and optimizing support to HCPs.
- 27 July 2025
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 12
Open AccessImpacts of the COVID-19 Pandemic on Chronic Kidney Disease Care: Perspectives of Health Care Providers
Background: The COVID-19 pandemic significantly disrupted health care delivery; however, limited research attention has addressed the impacts of the pandemic specifically on renal-based health care. Objective: The aim of the study was to understand the health and psychosocial impacts of the COVID-19 pandemic on care delivery as well as on health care providers (HCPs). Design: A qualitative Interpretive Description approach was used. Setting: Participants were recruited from kidney care units in Alberta and Ontario, Canada. Participants: 46 interdisciplinary HCPs providing kidney care during the pandemic participated in the study. Participants comprised pediatric (n=9) and adult (n=37) HCPs. Methods: Qualitative focus groups were facilitated. They were conducted using Zoom (Version 6.3.11). Results: Research results indicated substantial strain on patients and HCPs during the COVID-19 pandemic, including mental health difficulties. For HCPs, moral distress was experienced from witnessing negative impacts of the pandemic and care shifts on patients. HCPs were further deleteriously affected by staffing shortages, facility limitations due to care interruptions and resource gaps in health and community systems. Conversely, participants identified concurrent benefits from pandemic-related shifts such as the rapid transition to virtual care. While virtual care imposed challenges for physical assessment of patients, patient convenience and increased access to HCPs were noted. With training, support and experience, HCPs and patients reported an appreciation for communication offered by virtual care where appropriate. Supportive unit leaders and peer support from HCP colleagues were viewed to make this difficult experience of the pandemic more manageable. HCPs drew strength in being able to support their patients despite the difficulties of the pandemic. Limitations: Firsthand experiences of patients and families were not offered in this article, although their perspectives were elicited in another arm of this study. A more specific focus on pediatric versus adult systems of care, and the impacts of the pandemic on various disciplines, would add depth to understanding the unique impacts of the pandemic on various areas of care and across disciplines. Conclusions: Study results call for the advancement of clinical care and heightened consideration of HCP needs in a pandemic. Included recommendations are ensuring sufficient resources, prudent use of communication technology, and optimizing support to HCPs.
- Open Access
Global prevalence of chronic kidney disease and associated risk factors in children and adolescents: protocol for a systematic review and meta-analysis
Introduction: While chronic kidney disease (CKD) is well characterised in adults, less is known about the prevalence of CKD in children and adolescents, where it is rare and associated with unique characteristics and implications for long-term health outcomes. This study protocol outlines a systematic review to assess the global prevalence of CKD in children and adolescents along with causes and associated risk factors. This is warranted to better characterise prevalence and to identify at-risk groups that would benefit from screening efforts. We will explore the risk and burden of CKD and its variations by sociodemographic characteristics (age group, race, sex/gender) and geographical regions (country, International Society of Nephrology region and income groups based on World Bank country classifications). Methods and analysis: We will conduct a systematic review of studies reporting on the prevalence of CKD in children and adolescents following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 (PRISMA-P-2015) and the PRISMA 2020 methodological guidelines (PRISMA 2020). Searches will be undertaken in the following databases with the date range from 2000 to date: Ovid MEDLINE, Ovid Embase, CINAHL, Cochrane Library, ProQuest Dissertations & Theses Citation Index (via Clarivate), Web of Science Core Collection, Google Scholar and grey literature sites (registries, government reports) to identify studies that report on the prevalence of CKD in children and adolescents from ages 0 to 18. The primary outcome will be the global prevalence of CKD in children and adolescents. Secondary outcomes will include the causes of and risk factors for CKD, and examining differences and temporal trends in CKD prevalence across countries, geographical regions, income levels and sociodemographic characteristics. Ethics and dissemination: No direct involvement with patient data will be used in this systematic review, as data will be obtained from previously published reports. Ethical approval is therefore not required. Our findings will be published in an open-access peer-reviewed journal and presented at scientific conferences. PROSPERO registration number: CRD42024547467.
Open AccessGlobal prevalence of chronic kidney disease and associated risk factors in children and adolescents: protocol for a systematic review and meta-analysis
Introduction: While chronic kidney disease (CKD) is well characterised in adults, less is known about the prevalence of CKD in children and adolescents, where it is rare and associated with unique characteristics and implications for long-term health outcomes. This study protocol outlines a systematic review to assess the global prevalence of CKD in children and adolescents along with causes and associated risk factors. This is warranted to better characterise prevalence and to identify at-risk groups that would benefit from screening efforts. We will explore the risk and burden of CKD and its variations by sociodemographic characteristics (age group, race, sex/gender) and geographical regions (country, International Society of Nephrology region and income groups based on World Bank country classifications). Methods and analysis: We will conduct a systematic review of studies reporting on the prevalence of CKD in children and adolescents following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 (PRISMA-P-2015) and the PRISMA 2020 methodological guidelines (PRISMA 2020). Searches will be undertaken in the following databases with the date range from 2000 to date: Ovid MEDLINE, Ovid Embase, CINAHL, Cochrane Library, ProQuest Dissertations & Theses Citation Index (via Clarivate), Web of Science Core Collection, Google Scholar and grey literature sites (registries, government reports) to identify studies that report on the prevalence of CKD in children and adolescents from ages 0 to 18. The primary outcome will be the global prevalence of CKD in children and adolescents. Secondary outcomes will include the causes of and risk factors for CKD, and examining differences and temporal trends in CKD prevalence across countries, geographical regions, income levels and sociodemographic characteristics. Ethics and dissemination: No direct involvement with patient data will be used in this systematic review, as data will be obtained from previously published reports. Ethical approval is therefore not required. Our findings will be published in an open-access peer-reviewed journal and presented at scientific conferences. PROSPERO registration number: CRD42024547467.
- Open Access
- 20 December 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (12) , e0004086
Disparities in kidney care in vulnerable populations: A multinational study from the ISN-GKHA
Vulnerable populations, such as the elderly, children, displaced people, and refugees, often encounter challenges in accessing healthcare. In this study, we used data from the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to describe kidney care access and delivery to vulnerable populations across countries and regions. Using data from an international survey of clinicians, policymakers, and patient advocates, we assessed the funding and coverage of vulnerable populations on all aspects of kidney replacement therapies (KRT). Overall, 167 countries or jurisdictions participated in the survey, representing 97.4% of the world’s population. Children had less access than adults to KRT: hemodialysis (HD) in 74% of countries, peritoneal dialysis (PD) in 53% of countries, and kidney transplantation (KT) in 80% of countries. Available nephrologist workforce for pediatric kidney care was much lower than for adults (0.69 per million population [pmp] vs 10.08 pmp). Refugees or displaced people with kidney failure did not have access to HD, PD, or KT in 21%, 33%, and 37% of the participating countries, respectively. Low-income countries (LICs) were less likely to provide KRT access to refugees compared to high-income countries (HICs): HD: 13% vs 22%; PD: 19% vs 61%; KT: 30% vs 44%. Testing for kidney disease was routinely offered to elderly people in only 61% of countries: LICs (45%), lower-middle-income countries (56%), upper-middle-income countries (54%), and HICs (75%). Equitable access to kidney care for vulnerable people, particularly for children and displaced people, remains an area of unmet need. Strategies are needed to address this issue.
- 20 December 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (12) , e0004086
Open AccessDisparities in kidney care in vulnerable populations: A multinational study from the ISN-GKHA
Vulnerable populations, such as the elderly, children, displaced people, and refugees, often encounter challenges in accessing healthcare. In this study, we used data from the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to describe kidney care access and delivery to vulnerable populations across countries and regions. Using data from an international survey of clinicians, policymakers, and patient advocates, we assessed the funding and coverage of vulnerable populations on all aspects of kidney replacement therapies (KRT). Overall, 167 countries or jurisdictions participated in the survey, representing 97.4% of the world’s population. Children had less access than adults to KRT: hemodialysis (HD) in 74% of countries, peritoneal dialysis (PD) in 53% of countries, and kidney transplantation (KT) in 80% of countries. Available nephrologist workforce for pediatric kidney care was much lower than for adults (0.69 per million population [pmp] vs 10.08 pmp). Refugees or displaced people with kidney failure did not have access to HD, PD, or KT in 21%, 33%, and 37% of the participating countries, respectively. Low-income countries (LICs) were less likely to provide KRT access to refugees compared to high-income countries (HICs): HD: 13% vs 22%; PD: 19% vs 61%; KT: 30% vs 44%. Testing for kidney disease was routinely offered to elderly people in only 61% of countries: LICs (45%), lower-middle-income countries (56%), upper-middle-income countries (54%), and HICs (75%). Equitable access to kidney care for vulnerable people, particularly for children and displaced people, remains an area of unmet need. Strategies are needed to address this issue.
- Open Access
- 26 July 2022
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 9
The Use of Indomethacin for Nocturnal Enuresis in Children With Nephrogenic Diabetes Insipidus: A Case Report and Review of the Literature
Rationale: Nocturnal enuresis is a common symptom of nephrogenic diabetes insipidus (NDI) in children. Published reports on the treatment of nocturnal enuresis in this population are scarce. Presenting concern of the patient: 2 brothers, aged 8 and 9 years, presented for outpatient pediatric nephrology follow-up. Despite being medically stable on their current medication regimen, they both experienced significant distress due to primary nocturnal enuresis, including decreased self-esteem and social stress. Diagnoses: The brothers had primary nocturnal enuresis related to their high urine output from NDI. Interventions: we describe a case of 2 brothers with NDI in whom indomethacin was added to their pharmacologic treatment specifically to address enuresis. Outcome: Both brothers experienced a significant decrease in the frequency of nocturnal enuresis and improvement in their perceived quality of life. Teaching points: Nocturnal enuresis is a bothersome symptom of NDI with adverse psychological effects. Indomethacin can improve nocturnal enuresis in some patients. Treatment with nonsteroidal anti-inflammatory drugs carries a risk of gastrointestinal and kidney side effects. We advocate for a patient-centered approach to the treatment of NDI which includes optimizing both the medical and the psychological needs of the patient.
- 26 July 2022
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 9
Open AccessThe Use of Indomethacin for Nocturnal Enuresis in Children With Nephrogenic Diabetes Insipidus: A Case Report and Review of the Literature
Rationale: Nocturnal enuresis is a common symptom of nephrogenic diabetes insipidus (NDI) in children. Published reports on the treatment of nocturnal enuresis in this population are scarce. Presenting concern of the patient: 2 brothers, aged 8 and 9 years, presented for outpatient pediatric nephrology follow-up. Despite being medically stable on their current medication regimen, they both experienced significant distress due to primary nocturnal enuresis, including decreased self-esteem and social stress. Diagnoses: The brothers had primary nocturnal enuresis related to their high urine output from NDI. Interventions: we describe a case of 2 brothers with NDI in whom indomethacin was added to their pharmacologic treatment specifically to address enuresis. Outcome: Both brothers experienced a significant decrease in the frequency of nocturnal enuresis and improvement in their perceived quality of life. Teaching points: Nocturnal enuresis is a bothersome symptom of NDI with adverse psychological effects. Indomethacin can improve nocturnal enuresis in some patients. Treatment with nonsteroidal anti-inflammatory drugs carries a risk of gastrointestinal and kidney side effects. We advocate for a patient-centered approach to the treatment of NDI which includes optimizing both the medical and the psychological needs of the patient.
- 3 March 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (8) , 1747-1757
Furosemide and albumin for the treatment of nephrotic edema: a systematic review
Background Edema is one of the cardinal clinical features of nephrotic syndrome (NS). It may vary from mild periorbital edema to severe generalized edema (anasarca). In patients where edema does not improve with prednisone therapy, the most common supportive medications are diuretics and albumin. However, due to the complex pathophysiology of edema formation in NS patients resulting in intravascular normovolemia or hypovolemia, optimal therapy for edema is still debated. We conducted a systematic review with the objective of evaluating the change in urine volume and urine sodium excretion after treatment with furosemide only versus furosemide with albumin in edematous patients with NS. Objectives (1) To evaluate efficacy of furosemide alone versus furosemide with albumin in the treatment of nephrotic edema in adults and children. (2) To compare the harms and benefits of different doses of furosemide for treating nephrotic edema. Search methods The search included all randomized or quasi-randomized controlled trials in English and French using MEDLINE, Embase, and CENTRAL Trials Registry of the Cochrane Collaboration using the Ovid interface. ClinicalTrials.gov and the International Clinical Trials Registry Platform were also searched. Selection criteria We included all RCTs and randomized cross-over studies in which furosemide and furosemide plus albumin are used in the treatment of children or adults with nephrotic edema. We excluded patients with hypoalbuminemia of non-renal origin and severe chronic kidney disease (CKD) with a glomerular filtration rate below 30 ml/min/1.74 m2 and patients with congenital NS. Data collection and analysis All abstracts were independently assessed by at least two authors to determine which studies met the inclusion criteria. Information on study design, methodology, and outcome data (urine volume, urine sodium excretion, adverse effects) from each identified study was entered into a separate data sheet. The differences in outcomes between the types of therapy were expressed as standardized mean difference (SMD) with 95% confidence intervals (CI). Results The search yielded 525 records, and after screening, five studies were included in the systematic review and four of those studies in the meta-analysis. One study had high risk of bias and the remaining three studies were deemed to have some concerns. Urine excretion was greater after treatment with furosemide and albumin versus furosemide (SMD 0.85, 95% CI = 0.33 to 1.38). Results for sodium excretion were inconclusive (SMD 0.37, 95%CI = − 0.28 to 1.02). Authors’ conclusions The current evidence is not sufficient to make definitive conclusions about the role of albumin in treating nephrotic edema. High-quality randomized studies with adequate samples sizes are needed. Including an assessment of intravascular volume status may be helpful. Trial registration Prospero: CRD4201808979. https://www.crd.york.ac.uk/PROSPERO Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information.
- 3 March 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (8) , 1747-1757
Furosemide and albumin for the treatment of nephrotic edema: a systematic review
Background Edema is one of the cardinal clinical features of nephrotic syndrome (NS). It may vary from mild periorbital edema to severe generalized edema (anasarca). In patients where edema does not improve with prednisone therapy, the most common supportive medications are diuretics and albumin. However, due to the complex pathophysiology of edema formation in NS patients resulting in intravascular normovolemia or hypovolemia, optimal therapy for edema is still debated. We conducted a systematic review with the objective of evaluating the change in urine volume and urine sodium excretion after treatment with furosemide only versus furosemide with albumin in edematous patients with NS. Objectives (1) To evaluate efficacy of furosemide alone versus furosemide with albumin in the treatment of nephrotic edema in adults and children. (2) To compare the harms and benefits of different doses of furosemide for treating nephrotic edema. Search methods The search included all randomized or quasi-randomized controlled trials in English and French using MEDLINE, Embase, and CENTRAL Trials Registry of the Cochrane Collaboration using the Ovid interface. ClinicalTrials.gov and the International Clinical Trials Registry Platform were also searched. Selection criteria We included all RCTs and randomized cross-over studies in which furosemide and furosemide plus albumin are used in the treatment of children or adults with nephrotic edema. We excluded patients with hypoalbuminemia of non-renal origin and severe chronic kidney disease (CKD) with a glomerular filtration rate below 30 ml/min/1.74 m2 and patients with congenital NS. Data collection and analysis All abstracts were independently assessed by at least two authors to determine which studies met the inclusion criteria. Information on study design, methodology, and outcome data (urine volume, urine sodium excretion, adverse effects) from each identified study was entered into a separate data sheet. The differences in outcomes between the types of therapy were expressed as standardized mean difference (SMD) with 95% confidence intervals (CI). Results The search yielded 525 records, and after screening, five studies were included in the systematic review and four of those studies in the meta-analysis. One study had high risk of bias and the remaining three studies were deemed to have some concerns. Urine excretion was greater after treatment with furosemide and albumin versus furosemide (SMD 0.85, 95% CI = 0.33 to 1.38). Results for sodium excretion were inconclusive (SMD 0.37, 95%CI = − 0.28 to 1.02). Authors’ conclusions The current evidence is not sufficient to make definitive conclusions about the role of albumin in treating nephrotic edema. High-quality randomized studies with adequate samples sizes are needed. Including an assessment of intravascular volume status may be helpful. Trial registration Prospero: CRD4201808979. https://www.crd.york.ac.uk/PROSPERO Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information.